Overview

Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Status:
Unknown status

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen (Vitamin K Antagonist (VKA), Clopigogrel and Aspirin) in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention (PCI).

Phase:

Phase 4

Details

Lead Sponsor:

Beijing Anzhen Hospital

Treatments:

Clopidogrel
Rivaroxaban
Warfarin